Qi Zheng Capsule on a chemotherapy treatment of advanced non-small cell lung cancer.docVIP

 PAGE \* MERGEFORMAT 10 Qi Zheng Capsule on a chemotherapy treatment of advanced non-small cell lung cancer [Abstract] Objective To observe Qi Zheng Capsule A Adjuvant chemotherapy in advanced non-small cell lung cancer (NSCLC clinical effect. Methods 50 patients with NSCLC were randomly divided into 2 groups. The treatment group of 30 patients, to Qi Zheng Capsule A Adjuvant chemotherapy in the control 20 cases, to chemotherapy treatment regimens .2 group 2 months. lesion size before and after treatment were observed and the toxicity of chemotherapy. Results curative effect solid tumor group 2 no significant difference (Pgt; 0.05, but 2 quality of life before and after treatment (KPS) score and side effects of chemotherapy were statistically significant comparison (P lt;0.05). Conclusion A Qi Zheng Capsule and chemotherapy can improve quality of life of patients with NSCLC, the toxicity of chemotherapy . [Keywords:] anti-cancer drug therapy combined with chemotherapy in non-cell carcinoma of the joint capsule quality of life [Abstract] Objective To observe the effect of Qijiafuzheng capsule assisted with chemotherapy on the treatment of advanced non-small cell lung cancer (NSCLC). Methods The procedure is to divide 50 patients suffering from NSCLC randomly into two groups. Patients in treatment group ( 30 cases) were4 treated with chemotherapy plus Qijiafuzheng capsule, 4 pills, three times a day. Patients in the control group (20 cases) were treated with single-chemotherapy. The period of treatment was two months in two groups. The size of disease focus and the toxicity of chemotherapy response were observed. Results The toxicity of chemotherapy in the treatment group was significantly lower than that in the control group (P lt;0.05). Score of life quality in the treatment group was significantly higher than that in the control group after treatment (P lt;0.05). There was no difference between two groups on effect for solid tumor (Pgt; 0.05). Conclus